Concepts (179)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lupus Erythematosus, Systemic | 9 | 2023 | 202 | 4.770 |
Why?
|
| Hospitalization | 12 | 2023 | 317 | 3.540 |
Why?
|
| Psoriasis | 3 | 2021 | 11 | 2.380 |
Why?
|
| Arthritis, Rheumatoid | 7 | 2022 | 358 | 2.350 |
Why?
|
| Scleroderma, Systemic | 3 | 2022 | 17 | 1.900 |
Why?
|
| Myositis | 7 | 2022 | 23 | 1.870 |
Why?
|
| Granulomatosis with Polyangiitis | 3 | 2022 | 10 | 1.820 |
Why?
|
| Lymphohistiocytosis, Hemophagocytic | 2 | 2023 | 8 | 1.750 |
Why?
|
| Acute Coronary Syndrome | 2 | 2022 | 15 | 1.670 |
Why?
|
| Inpatients | 9 | 2022 | 141 | 1.660 |
Why?
|
| Patient Readmission | 3 | 2023 | 123 | 1.550 |
Why?
|
| Brain Ischemia | 2 | 2022 | 71 | 1.490 |
Why?
|
| Adult | 26 | 2023 | 8604 | 1.270 |
Why?
|
| Dermatomyositis | 4 | 2023 | 13 | 1.230 |
Why?
|
| Hospital Mortality | 6 | 2023 | 141 | 1.170 |
Why?
|
| Polymyositis | 4 | 2023 | 9 | 1.150 |
Why?
|
| Humans | 46 | 2023 | 29361 | 1.150 |
Why?
|
| Creatine Kinase | 6 | 2015 | 33 | 0.960 |
Why?
|
| Rheumatic Diseases | 3 | 2021 | 56 | 0.930 |
Why?
|
| Churg-Strauss Syndrome | 1 | 2022 | 2 | 0.900 |
Why?
|
| Retrospective Studies | 17 | 2023 | 3273 | 0.890 |
Why?
|
| Sarcoidosis | 1 | 2022 | 13 | 0.880 |
Why?
|
| Lung Diseases | 1 | 2022 | 46 | 0.860 |
Why?
|
| Vasculitis, Central Nervous System | 1 | 2022 | 4 | 0.860 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2022 | 4 | 0.860 |
Why?
|
| Vasospasm, Intracranial | 1 | 2022 | 17 | 0.850 |
Why?
|
| Antirheumatic Agents | 6 | 2013 | 92 | 0.850 |
Why?
|
| Gout | 1 | 2022 | 8 | 0.850 |
Why?
|
| Still's Disease, Adult-Onset | 1 | 2022 | 2 | 0.840 |
Why?
|
| Lung Diseases, Interstitial | 1 | 2022 | 12 | 0.840 |
Why?
|
| Immunoglobulin G | 6 | 2013 | 129 | 0.840 |
Why?
|
| United States | 9 | 2022 | 2332 | 0.830 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 1 | 2021 | 11 | 0.830 |
Why?
|
| Microscopic Polyangiitis | 1 | 2021 | 2 | 0.820 |
Why?
|
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2021 | 2 | 0.820 |
Why?
|
| Lupus Nephritis | 1 | 2021 | 28 | 0.810 |
Why?
|
| Cerebrovascular Disorders | 1 | 2022 | 132 | 0.750 |
Why?
|
| Atrial Fibrillation | 1 | 2021 | 183 | 0.670 |
Why?
|
| Rheumatology | 2 | 2022 | 81 | 0.670 |
Why?
|
| Aspartate Aminotransferases | 2 | 2015 | 18 | 0.660 |
Why?
|
| Alanine Transaminase | 2 | 2015 | 21 | 0.660 |
Why?
|
| Tuberculosis | 5 | 2013 | 25 | 0.650 |
Why?
|
| Stroke | 1 | 2022 | 293 | 0.650 |
Why?
|
| Risk Factors | 6 | 2023 | 2446 | 0.600 |
Why?
|
| Tumor Necrosis Factor-alpha | 5 | 2008 | 215 | 0.540 |
Why?
|
| Paracentesis | 1 | 2015 | 4 | 0.520 |
Why?
|
| Arthritis, Psoriatic | 3 | 2017 | 17 | 0.510 |
Why?
|
| Fluoroscopy | 1 | 2015 | 52 | 0.510 |
Why?
|
| Purpura, Thrombotic Thrombocytopenic | 2 | 2005 | 11 | 0.490 |
Why?
|
| Spondylitis, Ankylosing | 3 | 2010 | 44 | 0.480 |
Why?
|
| Antibodies, Monoclonal | 4 | 2013 | 260 | 0.470 |
Why?
|
| Uveoparotid Fever | 1 | 2013 | 1 | 0.470 |
Why?
|
| Arthritis, Infectious | 3 | 2017 | 59 | 0.470 |
Why?
|
| Parotid Gland | 1 | 2013 | 15 | 0.460 |
Why?
|
| Female | 20 | 2023 | 16211 | 0.450 |
Why?
|
| Etanercept | 7 | 2017 | 23 | 0.430 |
Why?
|
| Tissue Plasminogen Activator | 2 | 2022 | 42 | 0.400 |
Why?
|
| Immunosuppressive Agents | 5 | 2017 | 132 | 0.390 |
Why?
|
| Hospitals | 2 | 2022 | 157 | 0.380 |
Why?
|
| Incidence | 3 | 2022 | 756 | 0.370 |
Why?
|
| Databases, Factual | 2 | 2022 | 330 | 0.370 |
Why?
|
| Length of Stay | 2 | 2021 | 317 | 0.340 |
Why?
|
| Immunoconjugates | 1 | 2008 | 10 | 0.320 |
Why?
|
| Middle Aged | 13 | 2023 | 9823 | 0.310 |
Why?
|
| Receptors, Tumor Necrosis Factor | 6 | 2013 | 33 | 0.280 |
Why?
|
| Male | 12 | 2023 | 15637 | 0.270 |
Why?
|
| Diagnosis, Differential | 3 | 2022 | 389 | 0.270 |
Why?
|
| Arthritis, Juvenile | 2 | 2009 | 8 | 0.260 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2009 | 18 | 0.250 |
Why?
|
| Neuromyelitis Optica | 1 | 2023 | 5 | 0.240 |
Why?
|
| Sjogren's Syndrome | 1 | 2023 | 4 | 0.240 |
Why?
|
| Tuberculosis, Gastrointestinal | 1 | 2003 | 2 | 0.240 |
Why?
|
| Peritonitis | 1 | 2003 | 15 | 0.230 |
Why?
|
| Autoimmune Diseases | 1 | 2023 | 61 | 0.220 |
Why?
|
| Pulmonary Alveoli | 1 | 2022 | 22 | 0.220 |
Why?
|
| Venous Thrombosis | 1 | 2023 | 42 | 0.220 |
Why?
|
| Hemiplegia | 1 | 2022 | 8 | 0.220 |
Why?
|
| Hemorrhage | 1 | 2022 | 75 | 0.210 |
Why?
|
| Paresis | 1 | 2022 | 9 | 0.210 |
Why?
|
| Vasoconstriction | 1 | 2022 | 24 | 0.210 |
Why?
|
| Aged | 7 | 2022 | 9447 | 0.210 |
Why?
|
| Heart Valve Diseases | 1 | 2021 | 22 | 0.210 |
Why?
|
| Antibodies, Antineutrophil Cytoplasmic | 1 | 2021 | 10 | 0.210 |
Why?
|
| Kidney | 1 | 2003 | 173 | 0.210 |
Why?
|
| Sepsis | 1 | 2023 | 144 | 0.200 |
Why?
|
| Autoantibodies | 1 | 2022 | 100 | 0.200 |
Why?
|
| Hospital Charges | 1 | 2021 | 17 | 0.200 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2015 | 100 | 0.190 |
Why?
|
| Young Adult | 4 | 2022 | 1935 | 0.190 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2013 | 113 | 0.180 |
Why?
|
| Treatment Outcome | 4 | 2022 | 3476 | 0.170 |
Why?
|
| Adolescent | 3 | 2022 | 2280 | 0.170 |
Why?
|
| Internship and Residency | 1 | 2022 | 211 | 0.170 |
Why?
|
| Prednisone | 2 | 2015 | 67 | 0.160 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1442 | 0.150 |
Why?
|
| Disease Management | 1 | 2017 | 114 | 0.140 |
Why?
|
| Hepatitis C, Chronic | 1 | 2017 | 78 | 0.140 |
Why?
|
| Methylprednisolone | 1 | 2015 | 24 | 0.130 |
Why?
|
| Metatarsophalangeal Joint | 1 | 2015 | 5 | 0.130 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 100 | 0.130 |
Why?
|
| Injections, Intra-Articular | 1 | 2015 | 88 | 0.120 |
Why?
|
| Wrist Joint | 1 | 2015 | 61 | 0.120 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2014 | 2 | 0.120 |
Why?
|
| Fructose-Bisphosphate Aldolase | 1 | 2014 | 4 | 0.120 |
Why?
|
| Infliximab | 3 | 2013 | 16 | 0.120 |
Why?
|
| Tuberculin Test | 3 | 2009 | 12 | 0.120 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2015 | 437 | 0.120 |
Why?
|
| Head | 1 | 2013 | 24 | 0.120 |
Why?
|
| Antitubercular Agents | 3 | 2013 | 16 | 0.110 |
Why?
|
| Adalimumab | 2 | 2013 | 16 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2007 | 1829 | 0.090 |
Why?
|
| Troponin T | 1 | 2009 | 4 | 0.090 |
Why?
|
| Troponin I | 1 | 2009 | 11 | 0.090 |
Why?
|
| Isoniazid | 1 | 2009 | 6 | 0.090 |
Why?
|
| Transaminases | 1 | 2009 | 6 | 0.090 |
Why?
|
| Methotrexate | 1 | 2009 | 41 | 0.090 |
Why?
|
| Vasculitis | 1 | 2009 | 32 | 0.090 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2013 | 770 | 0.080 |
Why?
|
| Myocardium | 1 | 2009 | 140 | 0.080 |
Why?
|
| Abatacept | 1 | 2008 | 8 | 0.080 |
Why?
|
| Liver | 1 | 2009 | 173 | 0.080 |
Why?
|
| Rituximab | 1 | 2008 | 53 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2008 | 38 | 0.080 |
Why?
|
| B-Lymphocytes | 1 | 2008 | 81 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2007 | 29 | 0.080 |
Why?
|
| T-Lymphocytes | 1 | 2008 | 212 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2014 | 1220 | 0.070 |
Why?
|
| Hip Joint | 1 | 2010 | 367 | 0.070 |
Why?
|
| ADAMTS13 Protein | 1 | 2005 | 5 | 0.070 |
Why?
|
| Metalloendopeptidases | 1 | 2005 | 24 | 0.070 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 107 | 0.060 |
Why?
|
| Risk Assessment | 2 | 2009 | 678 | 0.060 |
Why?
|
| ADAM Proteins | 1 | 2005 | 64 | 0.060 |
Why?
|
| Muscle Strength | 2 | 2015 | 127 | 0.060 |
Why?
|
| Therapeutic Irrigation | 1 | 2004 | 66 | 0.060 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2004 | 50 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2006 | 324 | 0.060 |
Why?
|
| Paraplegia | 1 | 2023 | 5 | 0.060 |
Why?
|
| Kidney Diseases | 1 | 2005 | 115 | 0.060 |
Why?
|
| Immunocompromised Host | 1 | 2003 | 45 | 0.060 |
Why?
|
| Seizures | 1 | 2023 | 87 | 0.060 |
Why?
|
| Biopsy, Needle | 1 | 2003 | 101 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 223 | 0.060 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2004 | 340 | 0.060 |
Why?
|
| Biopsy | 1 | 2003 | 234 | 0.050 |
Why?
|
| Immunohistochemistry | 1 | 2003 | 391 | 0.050 |
Why?
|
| Internal Medicine | 1 | 2022 | 32 | 0.050 |
Why?
|
| Antibodies, Antiphospholipid | 1 | 2021 | 26 | 0.050 |
Why?
|
| Teaching | 1 | 2022 | 62 | 0.050 |
Why?
|
| Physical Examination | 1 | 2022 | 117 | 0.050 |
Why?
|
| Echocardiography | 1 | 2021 | 171 | 0.050 |
Why?
|
| Biomarkers | 2 | 2014 | 692 | 0.050 |
Why?
|
| Obesity | 1 | 2023 | 290 | 0.050 |
Why?
|
| Clinical Competence | 1 | 2022 | 230 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2021 | 638 | 0.050 |
Why?
|
| Liver Function Tests | 1 | 2017 | 24 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2017 | 113 | 0.040 |
Why?
|
| Viral Load | 1 | 2017 | 199 | 0.040 |
Why?
|
| Safety-net Providers | 1 | 2015 | 8 | 0.030 |
Why?
|
| Pulse Therapy, Drug | 1 | 2015 | 3 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2015 | 76 | 0.030 |
Why?
|
| Drug Therapy, Combination | 1 | 2015 | 241 | 0.030 |
Why?
|
| Pituitary Gland | 1 | 2014 | 8 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 55 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2015 | 329 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2014 | 41 | 0.030 |
Why?
|
| Latent Tuberculosis | 1 | 2013 | 2 | 0.030 |
Why?
|
| Quebec | 1 | 2013 | 3 | 0.030 |
Why?
|
| Europe | 1 | 2013 | 81 | 0.030 |
Why?
|
| Mass Screening | 1 | 2013 | 177 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 788 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2015 | 4851 | 0.020 |
Why?
|
| Acute Disease | 1 | 2010 | 226 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 1618 | 0.020 |
Why?
|
| Myocardial Ischemia | 1 | 2009 | 50 | 0.020 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2004 | 6 | 0.020 |
Why?
|
| Risk | 1 | 2004 | 217 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2009 | 1939 | 0.010 |
Why?
|
| Child | 1 | 2004 | 1345 | 0.010 |
Why?
|